Aizen Therapeutics

About

Aizen Therapeutics is an AI-native biotechnology company headquartered in San Diego that develops oral peptide therapeutics for chronic immune disorders. The company uses its proprietary DaX platform, a foundation model developed by Caltech faculty, to design peptides incorporating non-canonical amino acids that extend beyond natural biology. Aizen's pipeline includes gut-restricted and systemic oral biologics, and the company collaborates with global biopharma partners to advance peptide-based therapeutics.

Product

Value proposition

Delivering Oral Biologics for patient benefit by designing modern peptide drugs with AI and advanced models to create effective oral peptide therapeutics for chronic immune disorders.

Founders

• David Van Valen — Scientific Founder
• Ajay Kshatriya — CEO and Co-Founder
• Todd Peterson — Co-Founder and SAB Chair

Products

Key features

Technologies

Target conditions

Care settings

Partnerships

Investors

News

• Aizen Therapeutics launches to develop mirror peptides · 2024-12-02T15:11:16.000Z
• Aizen Therapeutics | LinkedIn · 2024-12-21T00:00:00.000Z
• Aizen Therapeutics Emerges from Stealth with $13M - San Diego Business Journal · 2024-11-26T13:00:29.000Z
• Aizen Therapeutics advances Mirror Peptides as new drug class · 2024-11-21T00:00:00.000Z
• Aizen Unlocks Therapeutic Frontiers with AI-Driven Peptide Design · 2024-11-21T11:00:56.000Z
• Aizen debuts with AI-driven ‘mirror peptide’ platform – San Diego Biotechnology Network · 2024-11-21T00:00:00.000Z

Browse related software

• Clinic software in CA
• Clinic software in San Diego
• Health AI software
• BioTech software
• MedTech software
• Digital Health software
• All clinic software companies A–Z

More links